About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 828951, 9 pages
http://dx.doi.org/10.1155/2010/828951
Review Article

Peroxisome Proliferator-Activated Receptor (PPAR): Balance for Survival in Parasitic Infections

1Department of Microbiology and Immunology, School of Medicine, Temple University, 3400 North Broad Street, Philadelphia, PA 19140, USA
2Department of Cell Biology and Neuroscience, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA

Received 31 August 2009; Accepted 10 November 2009

Academic Editor: Luis I. Terrazas

Copyright © 2010 Marion M. Chan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Michalik, J. Auwerx, J. P. Berger, et al., “International union of pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. Zieleniak, M. Wójcik, and L. A. Woźniak, “Structure and physiological functions of the human peroxisome proliferator-activated receptor γ,” Archivum Immunologiae et Therapiae Experimentalis, vol. 56, no. 5, pp. 331–345, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. Y. Zhu, C. Qi, J. R. Korenberg, et al., “Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 17, pp. 7921–7925, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Sundvold and S. Lien, “Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 383–390, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. V. Zoete, A. Grosdidier, and O. Michielin, “Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 915–925, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. P. Tontonoz and B. M. Spiegelman, “Fat and beyond: the diverse biology of PPARγ,” Annual Review of Biochemistry, vol. 77, pp. 289–312, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. N. S. Tan, L. Michalik, B. Desvergne, and W. Wahli, “Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes,” Journal of Steroid Biochemistry and Molecular Biology, vol. 93, no. 2–5, pp. 99–105, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. D. S. Straus and C. K. Glass, “Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms,” Trends in Immunology, vol. 28, no. 12, pp. 551–558, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. F. O. Martinez, L. Helming, and S. Gordon, “Alternative activation of macrophages: an immunologic functional perspective,” Annual Review of Immunology, vol. 27, pp. 451–483, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. J. L. Reyes and L. I. Terrazas, “The divergent roles of alternatively activated macrophages in helminthic infections,” Parasite Immunology, vol. 29, no. 12, pp. 609–619, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. G. Raes, A. Beschin, G. H. Ghassabeh, and P. De Baetselier, “Alternatively activated macrophages in protozoan infections,” Current Opinion in Immunology, vol. 19, no. 4, pp. 454–459, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. W. Noël, G. Raes, G. H. Ghassabeh, et al., “Alternatively activated macrophages during parasite infections,” Trends in Parasitology, vol. 20, no. 3, pp. 126–133, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. S. A. Kliewer, B. M. Forman, B. Blumberg, et al., “Differential expression and activation of a family of murine peroxisome proliferator-activated receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 15, pp. 7355–7359, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. M. E. Greene, B. Blumberg, O. W. McBride, et al., “Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping,” Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995. View at Scopus
  16. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Ricote, J. T. Huang, J. S. Welch, and C. K. Glass, “The peroxisome proliferator-activated receptor (PPARγ) as a regulator of monocyte/macrophage function,” Journal of Leukocyte Biology, vol. 66, no. 5, pp. 733–739, 1999. View at Scopus
  18. L. Széles, D. Töröcsik, and L. Nagy, “PPARγ in immunity and inflammation: cell types and diseases,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1014–1030, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels, “Regulation of macrophage functions by PPAR-α, PPAR-γ, and LXRs in mice and men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1050–1059, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. X. Y. Yang, L. H. Wang, and W. L. Farrar, “A role for PPARγ in the regulation of cytokines in immune cells and cancer,” PPAR Research, vol. 2008, Article ID 961753, 12 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. Y. Yang, A. R. Gocke, A. Lovett-Racke, P. D. Drew, and M. K. Racke, “PPAR α regulation of the immune response and autoimmune encephalomyelitis,” PPAR Research, vol. 2008, Article ID 546753, 6 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. J. T. Huang, J. S. Welch, M. Ricote, et al., “Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999.
  23. M.-S. Yang, K.-A. Ji, S.-B. Jeon, et al., “Interleukin-13 enhances cyclooxygenase-2 expression in activated rat brain microglia: implications for death of activated microglia,” Journal of Immunology, vol. 177, no. 2, pp. 1323–1329, 2006. View at Scopus
  24. T. Shimizu, “Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 123–150, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. R. B. Clark, “The role of PPARs in inflammation and immunity,” Journal of Leukocyte Biology, vol. 71, no. 3, pp. 388–400, 2002. View at Scopus
  26. R. A. Daynes and D. C. Jones, “Emerging roles of PPARs in inflammation and immunity,” Nature Reviews Immunology, vol. 2, no. 10, pp. 748–759, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. Castrillo and P. Tontonoz, “Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation,” Annual Review of Cell and Developmental Biology, vol. 20, pp. 455–480, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. S. J. Bensinger and P. Tontonoz, “Integration of metabolism and inflammation by lipid-activated nuclear receptors,” Nature, vol. 454, no. 7203, pp. 470–477, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. A. Szanto and L. Nagy, “The many faces of PPARγ: anti-inflammatory by any means?” Immunobiology, vol. 213, no. 9-10, pp. 789–803, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. S. Dasgupta, A. Roy, M. Jana, D. M. Hartley, and K. Pahan, “Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-α,” Molecular Pharmacology, vol. 72, no. 4, pp. 934–946, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. T. Hänscheid, T. J. Egan, and M. P. Grobusch, “Haemozoin: from melatonin pigment to drug target, diagnostic tool, and immune modulator,” Lancet Infectious Diseases, vol. 7, no. 10, pp. 675–685, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. O. A. Skorokhod, M. Alessio, B. Mordmüller, P. Arese, and E. Schwarzer, “Hemozoin (malarial pigment) inhibits differentiation and maturation of human monocyte-derived dendritic cells: a peroxisome proliferator-activated receptor-γ-mediated effect,” Journal of Immunology, vol. 173, no. 6, pp. 4066–4074, 2004. View at Scopus
  33. B. C. Urban and S. Todryk, “Malaria pigment paralyzes dendritic cells,” Journal of Biology, vol. 5, no. 2, article 4, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. M. M. Chen, L. Shi, and D. J. Sullivan Jr., “Haemoproteus and Schistosoma synthesize heme polymers similar to Plasmodium hemozoin and β-hematin,” Molecular and Biochemical Parasitology, vol. 113, no. 1, pp. 1–8, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. M. F. Oliveira, S. W. Kycia, A. Gomez, et al., “Structural and morphological characterization of hemozoin produced by Schistosoma mansoni and Rhodnius prolixus,” FEBS Letters, vol. 579, no. 27, pp. 6010–6016, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. M. D. Carter, S. Reese Harry, and D. W. Wright, “Identification of hydroxyeicosatetraenoic acid components of schistosomal hemozoin,” Biochemical and Biophysical Research Communications, vol. 363, no. 3, pp. 867–872, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. T. J. Egan, “Haemozoin formation,” Molecular and Biochemical Parasitology, vol. 157, no. 2, pp. 127–136, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. G. L. Bannenberg, J. Aliberti, S. Hong, A. Sher, and C. Serhan, “Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis,” Journal of Experimental Medicine, vol. 199, no. 4, pp. 515–523, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. W. R. Henderson Jr. and E. Y. Chi, “Cytotoxic activity of 13-hydroxyoctadecadienoic acid against Toxoplasma gondii,” Parasitology, vol. 105, no. 3, pp. 343–347, 1992. View at Scopus
  40. D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to Leishmania major in mice,” Nature Reviews Immunology, vol. 2, no. 11, pp. 845–858, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. J. I. Odegaard, R. R. Ricardo-Gonzalez, and M. H. Goforth, “Macrophage-specific PPARγ controls alternative activation and improves insulin resistance,” Nature, vol. 447, no. 7148, pp. 1116–1120, 2007.
  42. N. Adapala and M. M. Chan, “Long-term use of an antiinflammatory, curcumin, suppressed type 1 immunity and exacerbated visceral leishmaniasis in a chronic experimental model,” Laboratory Investigation, vol. 88, no. 12, pp. 1329–1339, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. A. Gallardo-Soler, C. Gómez-Nieto, M. L. Campo, et al., “Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-γ/δ-mediated effect that links lipid metabolism and immunity,” Molecular Endocrinology, vol. 22, no. 6, pp. 1394–1402, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. X.-Q. Wei, I. G. Charles, A. Smith, et al., “Altered immune responses in mice lacking inducible nitric oxide synthase,” Nature, vol. 375, no. 6530, pp. 408–411, 1995. View at Scopus
  45. H. W. Murray and F. Nathan, “Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani,” Journal of Experimental Medicine, vol. 189, no. 4, pp. 741–746, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Chan, N. S. Adapala, and D. Fong, “Curcumin overcomes the inhibitory effect of nitric oxide on Leishmania,” Parasitology Research, vol. 96, no. 1, pp. 49–56, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. Berry, P. Balard, A. Coste, et al., “IL-13 induces expression of CD36 in human monocytes through PPARγ activation,” European Journal of Immunology, vol. 36, no. 6, pp. 1642–1652, 2007.
  48. A. Nencioni, F. Grunebach, A. Zobywlaski, C. Denzlinger, W. Brugger, and P. Brossart, “Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor γ,” Journal of Immunology, vol. 169, no. 3, pp. 1228–1235, 2002. View at Scopus
  49. L. Serghides, T. G. Smith, S. N. Patel, and K. C. Kain, “CD36 and malaria: friends or foes?” Trends in Parasitology, vol. 19, no. 10, pp. 461–469, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Areschoug and S. Gordon, “Scavenger receptors: role in innate immunity and microbial pathogenesis,” Cellular Microbiology, vol. 11, no. 8, pp. 1160–1169, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  51. R. L. Silverstein and M. Febbraio, “CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior,” Science Signaling, vol. 2, no. 72, 2009. View at Scopus
  52. L. Serghides and K. C. Kain, “Peroxisome proliferator-activated receptor γ-retinoid X receptor agonists increase CD36-dependent phagocytosis of Plasmodium falciparum-parasitized erythrocytes and decrease malaria-induced TNFα secretion by monocytes/macrophages,” Journal of Immunology, vol. 166, no. 11, pp. 6742–6748, 2001. View at Scopus
  53. T. G. Smith, L. Serghides, S. N. Patel, M. Febbraio, R. L. Silverstein, and K. C. Kain, “CD36-mediated nonopsonic phagocytosis of erythrocytes infected with stage I and IIA gametocytes of Plasmodium falciparum,” Infection and Immunity, vol. 71, no. 1, pp. 393–400, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. S. N. Patel, L. Serghides, T. G. Smith, et al., “CD36 mediates the phagocytosis of Plasmodium falciparum-infected erythrocytes by rodent macrophages,” Journal of Infectious Diseases, vol. 189, no. 2, pp. 204–213, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  55. K. Ayi, S. N. Patel, L. Serghides, T. G. Smith, and K. C. Kain, “Nonopsonic phagocytosis of erythrocytes infected with ring-stage Plasmodium falciparum,” Infection and Immunity, vol. 73, no. 4, pp. 2559–2563, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. L. Serghides and K. C. Kain, “Peroxisome proliferator-activated receptor γ and retinoid X receptor agonists have minimal effects on the interaction of endothelial cells with Plasmodium falciparum-infected erythrocytes,” Infection and Immunity, vol. 73, no. 2, pp. 1209–1213, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. L. Serghides, S. N. Patel, K. Ayi, et al., “Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria,” Journal of Infectious Diseases, vol. 199, no. 10, pp. 1536–1545, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. D. R. Herbert, C. Hölscher, M. Mohrs, et al., “Alternative macrophage activation is essential for survival during schistosomiasis and downmodulates T helper 1 responses and immunopathology,” Immunity, vol. 20, no. 5, pp. 623–635, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Gervois, J. C. Fruchart, and B. Staels, “Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors,” Nature Clinical Practice Endocrinology and Metabolism, vol. 3, no. 2, pp. 145–156, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. H. Chen, Y. W. He, W. Q. Liu, and J. H. Zhang, “Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum,” World Journal of Gastroenterology, vol. 14, no. 18, pp. 2905–2911, 2008. View at Publisher · View at Google Scholar
  61. F. Ondrey, “Peroxisome proliferator-activated receptor γ pathway targeting in carcinogenesis: implications for chemoprevention,” Clinical Cancer Research, vol. 15, no. 1, pp. 2–8, 2009. View at Publisher · View at Google Scholar · View at PubMed
  62. P. Balakumar, M. Rose, S. S. Ganti, et al., “PPAR dual agonists: are they opening Pandora's box?” Pharmacological Research, vol. 56, no. 2, pp. 91–98, 2007. View at Publisher · View at Google Scholar · View at PubMed
  63. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1065–1081, 2007. View at Publisher · View at Google Scholar · View at PubMed